OBiO Technology to be featured at American Society of Gene & Cell Therapy exhibition

OBiO Technology, a leading contract development and manufacturing organization for cell and gene therapy, is set to showcase its latest innovations at the American Society of Gene & Cell Therapy conference in Maryland, USA from May 7th to 11th. The company will present 9 posters highlighting their groundbreaking achievements in the gene therapy domain.

Among the presentations are three self-developed patented achievements, four advancements in process optimization, and two cutting-edge technology introductions. These milestones demonstrate OBiO Technology’s commitment to enhancing vector yield and efficiency, refining therapeutic processes, and reducing production costs.

The company’s experts will be on hand to discuss how their viral vector platform accelerates development timelines, de-risks manufacturing, and ensures high product quality at a lower cost. CEO Javier Jia Guo expressed excitement about participating in the conference, stating that OBiO Technology remains dedicated to innovation and problem-solving in the gene and cell therapy industry.

OBiO Technology’s state-of-the-art facility and expertise in vectorology studies, functional genomics, and process development position them as a key player in advancing gene therapy for better lives. Their commitment to delivering high-quality services across all stages of development underscores their mission to make a positive impact on populations worldwide.

Don’t miss the opportunity to visit OBiO Tech’s booth #1644 at the ASGCT conference to learn more about their cutting-edge solutions in gene and cell therapy.